The global neurodegenerative diseases drugs market size was valued at USD 54.22 billion in 2024. The market is projected to grow from USD 58.22 billion in 2025 to USD 85.40 billion by the end of 2032, exhibiting a CAGR of 5.6% during the forecast period 2025-2032. North America dominated the neurodegenerative diseases drugs market with a market share of 51.77% in 2025.

Market Overview

The neurodegenerative diseases drugs market ****is experiencing transformative growth, driven by healthcare technology innovations, expanding digital ecosystems, and a rising focus on preventive and personalized medicine. Between 2018  and 2032, the industry is projected to expand significantly, supported by higher healthcare budgets, evolving patient expectations, and growing investments in infrastructure and research.

Demographic shifts—including aging populations, urbanization, and the rising prevalence of chronic diseases—are further accelerating demand for advanced healthcare services and solutions worldwide.

neurodegenerative diseases drugs market represents a broad set of products, solutions, and services that enhance care delivery, improve safety, and ensure compliance. These solutions are crucial for reducing risks, protecting patients, enhancing diagnostic and treatment efficiency, and maintaining regulatory adherence.

Continue reading for more details:

https://www.fortunebusinessinsights.com/neurodegenerative-diseases-drugs-market-100661

Key Market Drivers

  1. Rising Patient Safety Concerns – Demand for tools that prevent medical errors and infections.
  2. Technological Advancements – Integration of AI, analytics, and automation for efficiency.
  3. Healthcare Expenditure Growth – Investments in infrastructure upgrades by governments and private players.
  4. Regulatory Pressure – Strict global safety standards driving adoption.
  5. Expansion in Emerging Markets – Improved healthcare infrastructure in Asia-Pacific, Latin America, and Africa.

Market Segmentation

The neurodegenerative diseases drugs market can be segmented as follows:

Key Findings / Summary

5.2. Market Analysis, Insightsand Forecast – By Drug Class

5.2.1Immunomodulators

5.2.2Interferons